ERYTECH announces a positive DSMB safety review following the treatment of the first twenty-four patients with eryaspase in its Phase 2 study in pancreatic cancer.
ERYTECH announces a positive DSMB safety review following the treatment of the first twenty-four patients with eryaspase in its Phase 2 study in pancreatic cancer.